Episódios

  • Does This Patient Have Volume Overload? The Rational Clinical Examination
    Feb 23 2026

    Accurate assessment of intravascular volume facilitates decisions about fluid management in patients with volume overload. Author Edmund A. Liles Jr, MD, of the University of Utah joins JAMA Associate Editor David Simel, MD, MHS, to discuss best evidence from physical exam findings including ultrasound, radiographs, and lab studies for determining volume overload in spontaneously breathing patients.

    Related Content:

    • Does This Patient Have Volume Overload?
    Exibir mais Exibir menos
    19 minutos
  • Type 1 Diabetes: Diagnosis and Management
    Feb 16 2026

    Type 1 diabetes affects approximately 2 million people in the US and 8.4 million people worldwide. Author Desmond Schatz, MD, of the University of Florida joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss current evidence regarding diagnosis and treatment of type 1 diabetes.

    Related Content:

    • Type 1 Diabetes
    Exibir mais Exibir menos
    17 minutos
  • Pharmaceutical Pricing: JAMA Talks With Mark Cuban
    Feb 12 2026

    Mark Cuban, entrepreneur, investor, and cofounder of the Mark Cuban Cost Plus Drug Company, joins JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss the role of pharmacy benefit managers, insurance formularies, and opaque pricing practices that shape how most Americans access prescription drugs. Hear why he thinks doctors are the good guys in a broken system.

    Related Content:

    • Pharmaceutical Pricing—JAMA Talks With Mark Cuban
    Exibir mais Exibir menos
    33 minutos
  • Medications for Opioid Use Disorder, Withdrawal, and Overdose
    Feb 11 2026

    Opioid use disorder is the third most prevalent substance use disorder worldwide. Author Alexander Walley, MB, MSc, of Boston Medical Center and Boston University joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the efficacy, safety, and practical considerations of treating patients with medications for opioid use disorder, opioid withdrawal, and opioid overdose.

    Related Content:

    • Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose
    Exibir mais Exibir menos
    24 minutos
  • Ovarian Cancer Prevention With Opportunistic Fallopian Tube Removal
    Feb 2 2026

    Ovarian cancer may be prevented with removal of the fallopian tubes during pelvic or select abdominal surgery in eligible women. This procedure, opportunistic salpingectomy, can be offered to more eligible women. Author Jurgen M. Piek, MD, PhD, of the Catharina Cancer Institute discusses this and more with JAMA Deputy Editor Linda Brubaker, MD, MS.

    Related Content:

    • Opportunistic Salpingectomy for Prevention of Tubo-Ovarian Carcinoma
    Exibir mais Exibir menos
    18 minutos
  • IgA Nephropathy in Adults
    Jan 26 2026

    IgA nephropathy is a chronic kidney disease involving deposition of IgA-containing immune complexes in the glomerulus, which often causes kidney failure within 10 to 20 years. Author Michelle Marie O'Shaughnessy, MB, BCh, BAO, MS, of Galway University joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the symptoms, risk factors, diagnosis, treatment, and prognosis of IgA nephropathy in adults.

    Related Content:

    • IgA Nephropathy in Adults
    Exibir mais Exibir menos
    27 minutos
  • Restless Legs Syndrome
    Jan 21 2026

    Restless legs syndrome is a sleep-related neurologic disorder that causes an overwhelming urge to move the limbs, which can cause substantial sleep disturbance. Author John W. Winkelman, MD, PhD, of Harvard Medical School joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the symptoms, risk factors, diagnosis, and treatment of restless legs syndrome.

    Related Content:

    • Restless Legs Syndrome
    Exibir mais Exibir menos
    23 minutos
  • A Conversation About the FDA's Regulation of Mifepristone
    Jan 12 2026

    Mifepristone used with misoprostol is the most common abortion regimen in the US. It is also a focal point of reproductive health policy and politics, with controversy over its legal status and regulation by the US Food and Drug Administration (FDA). Author G. Caleb Alexander, MD, MS, from Johns Hopkins discusses this and more with JAMA Deputy Editor Joseph S. Ross, MD, MHS.

    Related Content:

    • The US Food and Drug Administration's Regulation of Mifepristone
    • Politics, Science, and the Future of FDA Drug Regulation
    Exibir mais Exibir menos
    21 minutos